Victory Capital Management
EIGR

Victory Capital Management’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Victory Capital Management’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-243
Closed -$50K – 3425
2020
Q1 		$50K Buy
243
+2
+0.8% +$638 ﹤0.01% 2767
2019
Q4 		$108K Buy
241
+108
+81% +$38.3K ﹤0.01% 2513
2019
Q3 		$41K Buy
+133
New +$43.2K ﹤0.01% 2771

Other funds holding EIGR

6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Victory Capital Management's EIGR Position: Q2 2020 in Review

Victory Capital Management sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2020, closing a stake of 243 shares — an estimated $50K sold.

Victory Capital Management first reported a position in EIGR in Q3 2019 and held it in 3 quarters. The position peaked at $108K in Q4 2019. 94 funds tracked by Wall St. Rank hold EIGR as of Q2 2020.

  • Victory Capital Management reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2020 after selling out during the quarter.
  • Victory Capital Management sold 243 Eiger BioPharmaceuticals, Inc. shares in Q2 2020, an estimated $50K.
  • Victory Capital Management first reported a position in Eiger BioPharmaceuticals, Inc. in Q3 2019 and held it in 3 quarters.
  • Victory Capital Management's Eiger BioPharmaceuticals, Inc. position peaked at $108K in Q4 2019.
  • 94 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2020.

Based on Victory Capital Management's 13F filing for Q2 2020, filed 7 Aug 2020.